Tanespimycin plus bortezomib in patients with relapsed and refractory multiple myeloma: Final results of a phase I/II study

被引：0

作者：

Richardson, P. G.

Chanan-Khan, A.

Lonial, S.

Krishnan, A.

Carroll, M.

Alsina, M.

Albitar, M.

Berman, D.

Kaplita, S.

Anderson, K.

机构：

[1] Dana Farber Canc Inst, Boston, MA 02115 USA

[2] Roswell Pk Canc Inst, Buffalo, NY 14263 USA

[3] Emory Univ, Sch Med, Atlanta, GA 30322 USA

[4] City Hope Comprehens Canc Ctr, Duarte, CA USA

[5] Sutter Reg Canc Inst, Sacramento, CA USA

[6] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[7] Nichols Inst, San Juan Capistrano, CA USA

[8] Bristol Myers Squibb Co, Princeton, NJ USA

[9] Bristol Myers Squibb Co, Wallingford, CT 06492 USA

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

8503

引用

页数：2